Drug Action
Lurasidone is a dopamine D2, 5-HT2A, 5-HT7, alpha2A- and alpha2C- adrenoceptor antagonist, and is a partial agonist at 5-HT1a receptors.
PDF page 438
Loading InternPractice…
Drug reference
Lurasidone is a dopamine D2, 5-HT2A, 5-HT7, alpha2A- and alpha2C- adrenoceptor antagonist, and is a partial agonist at 5-HT1a receptors.
PDF page 438
Schizophrenia ▶BY MOUTH ▶Adult: Initially 37 mg once daily, increased if necessary up to 148 mg once daily Schizophrenia when given with concomitant moderate CYP3A4 inhibitors (e.g. diltiazem, erythromycin, fluconazole, and verapamil) ▶BY MOUTH ▶Adult: Initially 18.5 mg once daily (max. per dose 74 mg once daily)
PDF page 438
High doses in elderly. susceptibility to QT- interval prolongation
PDF page 438
→Appendix 1: lurasidone
PDF page 438
▶Common or very common Anxiety. drooling. fatigue. gastrointestinal discomfort. muscle complaints. musculoskeletal stiffness. nausea. oculogyric crisis. oral disorders. pain. psychiatric disorders. sleep disorders ▶Uncommon Appetite decreased. dysarthria. dysuria. gait abnormal. gastrointestinal disorders. hot flush. hyperhidrosis. hypertension. joint stiffness. nasopharyngitis. vision blurred ▶Rare or very rare Eosinophilia. rhabdomyolysis ▶Frequency not known Anaemia. angina pectoris. angioedema. atrioventricular block. breast abnormalities. diarrhoea. dysmenorrhoea. dysphagia. pruritus. renal failure. Stevens-Johnson syndrome. suicidal behaviour. vertigo
PDF page 438
Use only if potential benefit outweighs risk— limited information available.
PDF page 438
Manufacturer advises caution in moderate to severe impairment (risk of increased exposure). Dose adjustments Manufacturer advises initially 18.5 mg once daily in moderate to severe impairment, increased if necessary up to 74 mg once daily in moderate impairment, or up to max. 37 mg once daily in severe impairment.
PDF page 438
Manufacturer advises use only if potential benefit outweighs risk if eGFR less than 15 mL/minute/1.73 m2. Dose adjustments Initially 18.5 mg once daily, up to max. 74 mg once daily if eGFR less than 50 mL/minute/1.73 m2.
PDF page 438
Patients on doses higher than 111 mg once daily whose treatment is interrupted for longer than 3 days should restart on 111 mg once daily and titrate to usual dose; for all other doses, restart on usual dose.
PDF page 438
There can be variation in the licensing of different medicines containing the same drug. Tablet CAUTIONARY AND ADVISORY LABELS 2, 21, 25 ▶Latuda (Sunovion Pharmaceuticals Europe Ltd) Lurasidone (as Lurasidone hydrochloride) 18.5 mg Latuda 18.5mg tablets | 28 tablet P £90.72 DT = £90.72 Lurasidone (as Lurasidone hydrochloride) 37 mg Latuda 37mg tablets | 28 tablet P £90.72 DT = £90.72 Lurasidone (as Lurasidone hydrochloride) 74 mg Latuda 74mg tablets | 28 tablet P £90.72 DT = £90.72 eiiii F 401
PDF page 438
Initially 37 mg once daily, increased if necessary
First-line fragment. Read the complete Indications and Dose section above.
PDF page 438
Initially 18.5 mg once daily (max. per dose 74 mg
First-line fragment. Read the complete Indications and Dose section above.
PDF page 438